TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06234605: A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

Sponsor: HiberCell, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 80 pts

Competing Trials Overlap

13 Active Trials

Excess Burn Exposure

$2,230,536

Rescue Site Savings

+$1,476,552

Unlock Full NCT06234605 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06234605 Rescue Dossier →